Cargando…

Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases

Retinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnichels, Sven, Simmang, David, Löscher, Marina, Herrmann, Andreas, de Vries, Jan Willem, Spitzer, Martin S., Hurst, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961589/
https://www.ncbi.nlm.nih.gov/pubmed/36839853
http://dx.doi.org/10.3390/pharmaceutics15020532
_version_ 1784895792162537472
author Schnichels, Sven
Simmang, David
Löscher, Marina
Herrmann, Andreas
de Vries, Jan Willem
Spitzer, Martin S.
Hurst, José
author_facet Schnichels, Sven
Simmang, David
Löscher, Marina
Herrmann, Andreas
de Vries, Jan Willem
Spitzer, Martin S.
Hurst, José
author_sort Schnichels, Sven
collection PubMed
description Retinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they potentially cause serious side effects, e.g., infections, bleeding within the eye or retinal detachment, especially when performed on a monthly basis, thus decreasing the injection frequency and lowering the desired drug dose. Therefore, a sustained released at the region of interest with a sustained release is desired. Recently, novel lipid-DNA nanoparticles (NPs) were shown to be an efficient drug delivery platform to the anterior segment of the eye. In this study, we investigated the distribution and tropism of the NPs when applied intravitreally, as a potential medication carrier to the posterior part of the eye. This technology is perfectly suited for the delivery of low molecular weight drugs to the back of the eye, which so far is greatly hindered by fast diffusion rates of the free drugs in the vitreous body and their intrinsically low retainability in ocular tissue. Excellent biodistribution, adherence and presence for up to five days was found for the different tested nanoparticles ex vivo and in vivo. In conclusion, our lipid-DNA based nanocarrier system was able to reach the retina within minutes and penetrate the retina providing potentially safe and long-term carrier systems for small molecules or nucleotide-based therapies.
format Online
Article
Text
id pubmed-9961589
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99615892023-02-26 Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases Schnichels, Sven Simmang, David Löscher, Marina Herrmann, Andreas de Vries, Jan Willem Spitzer, Martin S. Hurst, José Pharmaceutics Article Retinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they potentially cause serious side effects, e.g., infections, bleeding within the eye or retinal detachment, especially when performed on a monthly basis, thus decreasing the injection frequency and lowering the desired drug dose. Therefore, a sustained released at the region of interest with a sustained release is desired. Recently, novel lipid-DNA nanoparticles (NPs) were shown to be an efficient drug delivery platform to the anterior segment of the eye. In this study, we investigated the distribution and tropism of the NPs when applied intravitreally, as a potential medication carrier to the posterior part of the eye. This technology is perfectly suited for the delivery of low molecular weight drugs to the back of the eye, which so far is greatly hindered by fast diffusion rates of the free drugs in the vitreous body and their intrinsically low retainability in ocular tissue. Excellent biodistribution, adherence and presence for up to five days was found for the different tested nanoparticles ex vivo and in vivo. In conclusion, our lipid-DNA based nanocarrier system was able to reach the retina within minutes and penetrate the retina providing potentially safe and long-term carrier systems for small molecules or nucleotide-based therapies. MDPI 2023-02-04 /pmc/articles/PMC9961589/ /pubmed/36839853 http://dx.doi.org/10.3390/pharmaceutics15020532 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schnichels, Sven
Simmang, David
Löscher, Marina
Herrmann, Andreas
de Vries, Jan Willem
Spitzer, Martin S.
Hurst, José
Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
title Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
title_full Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
title_fullStr Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
title_full_unstemmed Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
title_short Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
title_sort lipid-dna nanoparticles as drug-delivery vehicles for the treatment of retinal diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961589/
https://www.ncbi.nlm.nih.gov/pubmed/36839853
http://dx.doi.org/10.3390/pharmaceutics15020532
work_keys_str_mv AT schnichelssven lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases
AT simmangdavid lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases
AT loschermarina lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases
AT herrmannandreas lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases
AT devriesjanwillem lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases
AT spitzermartins lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases
AT hurstjose lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases